免疫检查点抑制剂诱导的自身免疫性多内分泌综合征2型:文献综述与管理方案
本文综述了截至2020年2月18日已发表的30例免疫检查点抑制剂(ICPis)诱导的自身免疫性多内分泌综合征2型(APS-2)病例,总结了其临床特征、自身抗体、HLA基因型及治疗,并提出筛查策略。结论强调内分泌科和肿瘤科医生应熟悉APS-2,对携带高风险HLA等位基因(HLA-DR4)的患者需密切监测。
要点
- ICPis诱导的APS-2罕见但可危及生命,需警惕糖尿病酮症酸中毒和急性肾上腺危象。
- 诊断ICPis诱导的自身免疫病后,尤其使用PD-1抑制剂者,应监测APS-2发生。
- 携带HLA-DR4高风险等位基因的患者需密切监测APS-2。
核心结论
- ICPis诱导的APS-2虽罕见但可致命,内分泌科和肿瘤科医生应熟悉其识别与监测。
研究设计与样本
- 综述类:检索PubMed、Web of Science、Cochrane Central Registry of Controlled Trials、ClinicalTrials.gov和Scopus至2020年2月18日,纳入病例报告,并参考FDA和EMA药物警戒注册数据。
主要发现
- 共汇总30例已发表或报告的ICPis诱导APS-2病例,总结了临床特征、自身抗体、HLA基因型和治疗。
关键数值与推荐
- 对ICPis诱导自身免疫病(尤其PD-1抑制剂)且携带HLA-DR4高风险等位基因的患者,需密切监测APS-2。
临床怎么用
- 内分泌科和肿瘤科医生应熟悉APS-2,对高危患者(尤其HLA-DR4阳性者)进行筛查和密切监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Immune checkpoint inhibitors (ICPis) targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1), and its ligand (PD-L1) are now approved to treat a variety of cancers. However, ICPis therapy is associated with a risk of immune-related adverse events (irAEs). Autoimmune polyendocrine syndrome type 2 (APS-2) is a rare endocrine irAE. EVIDENCE ACQUISITION: Several databases (PubMed, Web of Science, Cochrane Central Registry of Controlled Trials, ClinicalTrials.gov, and Scopus) were searched up to February 18, 2020, for case reports on endocrine irAEs and ICPis. The reported side effects and adverse events of the ICPis therapy in the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) adverse events pharmacovigilance registries are also included. EVIDENCE SYNTHESIS: Here, we provide an overview of all published and reported cases (n = 30) of ICPis-induced APS-2. We summarize the clinical characteristics, autoantibodies, human leukocyte antigen (HLA) genotypes, and therapies and propose an APS-2 screening strategy. CONCLUSIONS: Given the life-threatening risks of endocrine dysfunction if it is not promptly recognized (such as diabetic ketoacidosis and acute adrenal crisis), physicians (especially endocrinologists and oncologists) should be familiar with APS-2. After diagnosis of an autoimmune disease induced by ICPis (especially PD-1 inhibitors), patients with a high-risk HLA allele (HLA-DR4) require close monitoring for the development of APS-2.
引用
- Shi Y, Shen M, Zheng X, et al. ICPis-Induced Autoimmune Polyendocrine Syndrome Type 2: A Review of the Literature and a Protocol for Optimal Management. J Clin Endocrinol Metab. 2020. PMID: 32905579. doi:10.1210/clinem/dgaa553
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。